| Outcome Measures: |
Primary: Change in body weight, Baseline to Week 26|Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations, Baseline to Week 26 and Week 52 | Secondary: Change in body weight, Baseline to Week 52|Change in fasting glycemic parameters, HbA1c, plasma glucose, Baseline to Week 26 and Week 52|Change in cardiometabolic parameters, Blood pressure, lipid concentrations, hs-CRP, Baseline to Week 26 and Week 52|Change in Patient Reported Outcomes (PRO) scores, Baseline to Week 26 and Week 52
|
| Locations: |
Royal Prince Alfred Hospital, Camperdown, New South Wales, 2050, Australia|Pendlebury Research, Cardiff, New South Wales, 2285, Australia|Australian Clinical Research Network, Maroubra, New South Wales, 2035, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, 2065, Australia|Illawara Diabetes Service, Wollongong, New South Wales, 2500, Australia|Q-Pharm, Herston, Queensland, 4006, Australia|Ipswich Research Institute, Ipswich, Queensland, 4305, Australia|AusTrials, Sherwood, Queensland, 4075, Australia|CMAX, Adelaide, South Australia, 5000, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|St. Vincent's Hospital, Fitzroy, Victoria, 3065, Australia|Barwon Health, Geelong, Victoria, 3220, Australia|Austin Health, Heidelberg West, Victoria, 3081, Australia|Emeritus Research, Malvern East, Victoria, 3145, Australia|Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, 3004, Australia|Keogh Institute for Medical Research, Nedlands, Western Australia, 6009, Australia
|
